Ipca Labs Piparia Facility Receives VAI Status From FDA
Ipca Laboratories on Thursday informed the exchanges that its Piparia (Silvassa) formulations manufacturing facility has received the status "Voluntary Action Indicated (VAI)" from USFDA after the regulator had conducted an inspection on the unit from 18th April 2023 to 26th April 2023. The inspection resulted in three observations under USFDA Form 483.
"We have now received a communication from USFDA that they have determined the inspection classification of this manufacturing facility as “Voluntary Action Indicated (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP)," the company said in an exchange filing.
According to the USFDA, voluntary action indicated (VAI) is defined as objectionable conditions or practices found, but the agency is not prepared to take or recommend any administrative or regulatory action.
The company's stock was trading 3.43 per cent higher at Rs 906.80 per scrip as of 10:55 IST on BSE.
